Thanks for the posts.
WEST HAVEN, CONNECTICUT --Wednesday, March 24, 2014 -- NanoViricides, Inc. (NYSE MKT: NNVC) announced today that a fundamental PCT patent application, on which the nanoviricides® technology is based, has resulted in additional issued patents in Australia and the Philippines.
"The issuance of the Australian patent is of particular importance because of the Company's interest in pursuing the initial human clinical trials in that country," said Eugene Seymour, MD, MPH, CEO of the Company, adding, "Australia offers significant advantages including financial incentives that would help us speed the development of our drugs towards licensure".
The Australian and Philippine patents have been allowed with a very broad range of claims to a large number of families of chemical structure compositions, pharmaceutical compositions, methods of making the same, and uses of the same.
NanoViricides, Inc. holds exclusive, perpetual, worldwide licenses to these technologies for a broad range of antiviral applications and diseases (see below).
"It is rewarding to see that both the Australian and Philippine patent offices recognized the novelty and the broad utility of the entire 'pi-polymer' class of materials as defined by the inventors, and granted a patent with sufficient scope to protect the whole of the invention, for all foreseeable pharmaceutical applications," said Dr. James Demers, PhD, JD, Gotham Patent Services LLC, who represents the inventors and directs the international patenting effort. He further added, "In addition, the inventors have also filed an original PCT application that covers the nanoviricides® anti-viral substances."
These compositions result in self-assembling polymers that we call "TheraCour®" polymers (or "pi-polymers"), and possess significant advantages over the earlier block-copolymer systems, hard nanoparticle systems, as well as liposomal and emulsion systems, that are now advancing in nanomedicines development.
The TheraCour polymers result in polymeric micelles that can be used to encapsulate active pharmaceutical ingredients (APIs) to develop superior drugs where needed. Of greater importance to NanoViricides, they are capable of direct targeting to any desired surface with defined specificity, such as a virus particle.
The current first generation nanoviricides® drug candidates have achieved very high levels of effectiveness only by employing the specific targeting ability of the TheraCour polymer systems. These first generation drugs did not require encapsulation of any additional APIs to achieve their high levels of effectiveness. The Company believes this has simplified the drug approval process for us, because the specifically targeted nanoviricide polymer we make is itself the drug in these cases.
AI
